|
|
|
|
| LEADER |
03012nma a2200409 u 4500 |
| 001 |
EB001979993 |
| 003 |
EBX01000000000000001142895 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a 9782889451197
|
| 020 |
|
|
|a 978-2-88945-119-7
|
| 100 |
1 |
|
|a Silvia Gregori
|
| 245 |
0 |
0 |
|a HLA-G-mediated Immune Tolerance: Past and New Outlooks
|h Elektronische Ressource
|
| 260 |
|
|
|b Frontiers Media SA
|c 2017
|
| 300 |
|
|
|a 1 electronic resource (92 p.)
|
| 653 |
|
|
|a Autoimmunity
|
| 653 |
|
|
|a Pregnancy
|
| 653 |
|
|
|a Cancer
|
| 653 |
|
|
|a Medicine / bicssc
|
| 653 |
|
|
|a HLA-G
|
| 653 |
|
|
|a polymorphisms
|
| 653 |
|
|
|a tolerance
|
| 653 |
|
|
|a Immuno-modulation
|
| 653 |
|
|
|a Infections
|
| 653 |
|
|
|a Exosomes
|
| 653 |
|
|
|a Pre-Eclampsia
|
| 700 |
1 |
|
|a Joel LeMaoult
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 490 |
0 |
|
|a Frontiers Research Topics
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3389/978-2-88945-119-7
|
| 856 |
4 |
0 |
|u http://journal.frontiersin.org/researchtopic/2452/hla-g-mediated-immune-tolerance-past-and-new-outlooks
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/49487
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The non-classical HLA class I molecule HLA-G is different from classical HLA class I molecules because of the low polymorphism in the coding region, the fact that HLA-G primary transcript is alternatively spliced in seven isoforms, and the inhibitory action on immune cells. Although HLA-G is low polymorphic, variants in both promoter and 3' un-translated region (UTR) of HLA-G locus regulate its expression. In healthy conditions, a basal level of HLA-G gene transcription is observed in most cells and tissues; however, translation into HLA-G protein is restricted to trophoblasts in the placenta, where it participates in promoting tolerance at the fetal-maternal interface. HLA-G is also expressed by thymic epitelial, cornea, mesenchymal stem cells, nail matrix, pancreatic beta cells, erythroid, and endothelial precursors. HLA-G can be neo-expressed in adult tissues in pathological conditions, and its expression has been documented autoimmune disorders, viral infections, and cancer. In the latter setting de novo HLA-G expression is associated with the capability of tumor cells to evade the immune control. In the last decade it has become evident that HLA-G expression on T cells and antigenpresenting cells confers to these cells tolerogenic properties. This Research Topic focused on i) summarizing updated clinical and immunological evidences that HLA-G expression is associate with beneficial or detrimental tolerance, ii) gathering new insights into the mechanisms governing the expression of HLA-G in healthy and pathological conditions, such as pre-eclampsia, and iii) examining the mechanisms underlying HLA-G mediated tolerance.
|